Damora Therapeutics is trading at $19.22, down -5.04%, amid broader risk-off pressure following explosions in Riyadh and a sharp oil-price jump.
- No clear company-specific announcement surfaced to explain the decline; the latest identified company release concerned employee inducement grants announced October 2.
- Reuters reported Brent above $105 and the 10-year Treasury yield at 5.34%, alongside pressure on U.S. stock futures.
- Healthcare was also weak, down 1.49% in the supplied sector context.